Evidence map›Paper›PMID 33592021›Full record

ArticlePloS one2021

Association of lung diffusion capacity with cardiac remodeling and risk of heart failure: The Framingham heart study.

Ibrahim Musa Yola, Albin Oh, Gary F Mitchell, George O'Connor, Susan Cheng, Ramachandran S Vasan, Vanessa Xanthakis

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Echocardiography in HIV Disease.Current cardiology reports · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Ibrahim Musa YolaSection of Preventive Medicine and Epidemiology, Department of Medicine, Boston University School of Medicine, Boston, MA, United States of America.ORCID 0000-0002-2898-9792
Albin OhDepartment of Medicine, Boston Medical Center, Boston, MA, United States of America.ORCID 0000-0002-4211-3113
Gary F MitchellCardiovascular Engineering, Inc., Norwood, MA, United States of America.
George O'ConnorDepartment of Medicine, Pulmonary Center, Boston Medical Center, Boston University, Boston, MA, United States of America.
Susan ChengSmidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States of America.ORCID 0000-0002-4977-036X
Ramachandran S VasanSection of Preventive Medicine and Epidemiology, Department of Medicine, Boston University School of Medicine, Boston, MA, United States of America.ORCID 0000-0001-7357-5970
Vanessa XanthakisSection of Preventive Medicine and Epidemiology, Department of Medicine, Boston University School of Medicine, Boston, MA, United States of America.ORCID 0000-0002-7352-621X
Boston University · USBoston Medical Center · USCedars-Sinai Medical Center · USNorwood Hospital · US

Funding

FRAMINGHAM HEART STUDY - YEAR 5 EXAM75N92019D00031 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI RAMACHANDRAN, VASAN · 2019 to 2024
$29.8M
Proteomic Profiling of Precise Exercise Pathophenotypes Across the HFpEF SpectrumR01HL131029 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI Gregory Dyer Lewis, Matthew G. Nayor · 2016 to 2026
$7.7M
Cardiac microstructure and the immune-inflammatory response to SARS-CoV-2R01HL131532 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI CHENG, SUSAN, LI, DEBIAO · 2016 to 2025
$6.6M
Multidisciplinary Training Program in Cardiovascular EpidemiologyT32HL125232 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Matthew G. Nayor, Vanessa Xanthakis · 2016 to 2026
$5.0M
Clinical, genetic and cardiometabolic risk correlates of the gut microbiomeR01HL131015 · NHLBI · BROAD INSTITUTE, INC. · PI RAMACHANDRAN, VASAN S, SHAW, STANLEY Y · 2016 to 2019
$3.8M
Proteomic Pathway Discovery in Cardiovascular DiseaseR01HL132320 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI GERSZTEN, ROBERT E, RAMACHANDRAN, VASAN S · 2016 to 2019
$3.4M
Mediators of Systemic Inflammation and Heart Failure Risk in the CommunityR01HL143227 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI CHENG, SUSAN · 2019 to 2022
$3.3M
Ventricular-vascular coupling in the elderly: lifecourse determinants, trajectories, and prognostic significanceR01HL142983 · NHLBI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CHENG, SUSAN, MITCHELL, GARY FRANK · 2019 to 2022
$3.2M
Nutriuretic Peptides, the Renin-Angiotensin System, and Metabolic Risk in ObesityR01HL086875 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI WANG, THOMAS J. · 2007 to 2010
$1.7M
THE FRAMINGHAM HEART STUDY-N01HC25195-268025195-268025195N01HC025195 · HC · TRUSTEES OF BOSTON UNIVERSITY · PI WOLF, PHILIP A · 2002 to 2006
–
NHLBI NIH HHS 75N92019D00031NHLBI NIH HHS HHSN268201500001CNHLBI NIH HHS HHSN268201500001INHLBI NIH HHS N01 HC025195NHLBI NIH HHS R01 HL086875NHLBI NIH HHS R01 HL131015NHLBI NIH HHS R01 HL131029NHLBI NIH HHS R01 HL131532NHLBI NIH HHS R01 HL132320NHLBI NIH HHS R01 HL142983NHLBI NIH HHS R01 HL143227NHLBI NIH HHS T32 HL125232
6 · The paper itself

Abstract

backgroundLung function abnormalities are ubiquitous in heart failure (HF). It is unclear, however, if abnormal lung diffusion capacity is associated with cardiac remodeling and antedates HF. We hypothesized that lower lung diffusion capacity for carbon monoxide (DLCO) is associated with worse left ventricular (LV) systolic and diastolic function cross-sectionally, and with higher risk of HF prospectively.

methodsWe evaluated 2423 Framingham Study participants (mean age 66 years, 55% women) free of HF who underwent routine echocardiography and pulmonary function tests. We used multivariable regression models to relate DLCO, forced vital capacity (FVC), and forced expiratory volume in 1 second (FEV1) to left ventricular ejection fraction (LVEF), left atrial (LA) emptying fraction (LAEF), E/e', E/A, LV mass, and LA diameter (LAD). Multivariable-adjusted Cox proportional hazards regression was used to relate DLCO, FEV1, and FVC to incident HF.

resultsIn multivariable-adjusted cross-sectional analyses, DLCO, FEV1, and FVC (dependent variables) were associated positively with LVEF (βDLCO = 0.208, βFEV1 = 0.021, and βFVC = 0.025 per 5% increment in LVEF; p<0.005 for all), and LAEF (βDLCO = 0.707, βFEV1 = 0.058 and βFVC = 0.058 per 5% increment in LAEF; p<0.002 for all). DLCO and FVC were inversely related to E/A (βDLCO = -0.289, βFVC = -0.047 per SD increment in E/A; p<0.001 for all). Additionally, DLCO, FEV1 and FVC were inversely related to HF risk (108 events, median follow-up 9.7 years; multivariable-adjusted hazard ratios per SD increment 0.90, 95% CI 0.86-0.95; 0.42, 95% CI 0.28-0.65, and 0.51, 95% CI 0.36-0.73, respectively). These results remained robust in analyses restricted to non-smokers.

conclusionsOur large community-based observations are consistent with the concept that lower lung diffusion capacity and expiratory flow rates are associated with cardiac remodeling and may antedate HF. Additional studies are needed to confirm our findings and to evaluate the prognostic utility of pulmonary function testing for predicting HF.

Indexed as

Pulmonary Diffusing CapacityVentricular RemodelingAgedEchocardiographyFemaleForced Expiratory VolumeHeart FailureHumansLongitudinal StudiesMaleRisk FactorsStroke VolumeVital Capacity

Identifiers

PMID33592021
PMCPMC7886141
OpenAlexW3131309942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.